Ganaxolon (1) – Ztalmy®
CDKL5 deficiency, adjunctive therapy, 2 to < 18 years
Characteristics
| Start date | 01.07.2026 |
|---|---|
| Resolution | 17.12.2026 – active procedure |
| INN | Ganaxolon |
| Brand name | Ztalmy® |
| Pharm. company | Immedica Pharma Germany GmbH |
| G-BA Procedure ID | D-1034 |
| Therapeutic area | Nervous system diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
| Ganaxolon (1) | Ztalmy® | Immedica Pharma Germany GmbH | CDKL5 deficiency, adjunctive therapy, 2 to < 18 years | n.d. | active procedure Orphan |
<< List of all resolutions